Daniel Meibom
Impact in
- Physiology top 10%
- Adenosine and Purinergic Signaling
-
- Multiple Myeloma Research and Treatments
Papers in
-
- Protein Degradation and Inhibitors 5
- Receptor Mechanisms and Signaling 3
- Ubiquitin and proteasome pathways 3
-
- Asymmetric Synthesis and Catalysis 2
- Co-authors
- Vasanthanathan Poongavanam (5 shared papers)Jan Kihlberg (5 shared papers)Anja Giese (3 shared papers)Máté Erdélyi (4 shared papers)Yoseph Atilaw (3 shared papers)Duy Nguyen (1 shared paper)Lutz Lehmann (3 shared papers)Stephan Siegel (1 shared paper)
- Journals
- Journal of Medicinal Chemistry (5 papers)ACS Medicinal Chemistry Letters (2 papers)ChemMedChem (2 papers)European Journal of Medicinal Chemistry (1 paper)ACS Omega (1 paper)
- Partner nations
- GermanySwedenUnited States
In The Last Decade
Daniel Meibom
14 papers receiving 345 citations
Peers
Comparison fields: 5 of 57
- Physiology 31
- Hematology 54
- Oncology 121
- Molecular Biology 271
- Organic Chemistry 56
Countries citing papers authored by Daniel Meibom
This map shows the geographic impact of Daniel Meibom's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Meibom with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Meibom more than expected).
Fields of papers citing papers by Daniel Meibom
This network shows the impact of papers produced by Daniel Meibom. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Meibom. The network helps show where Daniel Meibom may publish in the future.
Co-authors
The 25 scholars most cited alongside Daniel Meibom, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2020 | 117 | |
| 2 | 2022 | 77 | |
| 3 | 2017 | 39 | |
| 4 | 2015 | 28 | |
| 5 | 2023 | 24 | |
| 6 | 2023 | 14 | |
| 7 | 1996 | 14 | |
| 8 | 2024 | 12 | |
| 9 | 2018 | 11 | |
| 10 | 2022 | 7 | |
| 11 | 2025 | 5 | |
| 12 | 2009 | 3 | |
| 13 | 2023 | 2 | |
| 14 | 2003 | 2 |
About Daniel Meibom
Daniel Meibom is a scholar working on Molecular Biology, Organic Chemistry, Oncology, Hematology and Pathology and Forensic Medicine, having authored 14 papers that have together received 355 indexed citations. Recurring topics across this work include Protein Degradation and Inhibitors (5 papers), Multiple Myeloma Research and Treatments (3 papers), Receptor Mechanisms and Signaling (3 papers), Ubiquitin and proteasome pathways (3 papers), Peptidase Inhibition and Analysis (3 papers), Cardiac electrophysiology and arrhythmias (2 papers), Asymmetric Synthesis and Catalysis (2 papers) and Cardiac Ischemia and Reperfusion (2 papers). The work is most often cited by research in Physiology (31 citations), Hematology (54 citations), Oncology (121 citations), Molecular Biology (271 citations) and Organic Chemistry (56 citations). Daniel Meibom has collaborated with scholars based in Germany, Sweden and United States. Frequent co-authors include Vasanthanathan Poongavanam, Jan Kihlberg, Anja Giese, Máté Erdélyi, Yoseph Atilaw, Duy Nguyen, Lutz Lehmann, Stephan Siegel, Ekkehard Winterfeldt and Joachim Mittendorf. Their work appears in journals such as Journal of Medicinal Chemistry, ACS Medicinal Chemistry Letters, ChemMedChem, European Journal of Medicinal Chemistry and ACS Omega.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.